Department of Immunology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.
J Transl Med. 2013 May 3;11:110. doi: 10.1186/1479-5876-11-110.
Studies of primary patient tumor xenografts grown in immunodeficient mice have shown that these tumors histologically and genetically closely resemble the original tumors. These patient xenograft models are becoming widely used for therapeutic efficacy studies. Because many therapies are directed at tumor stromal components and because the tumor microenvironment also is known to influence the response of a tumor to therapy, it is important to understand the nature of the stroma and, in particular, the vascular supply of patient xenografts.
Patient tumor xenografts were established by implanting undisrupted pieces of patient tumors in SCID mice. For this study, formalin fixed, paraffin embedded specimens from several types of solid tumors were selected and, using species-specific antibodies which react with formalin fixed antigens, we analyzed the species origin of the stroma and blood vessels that supported tumor growth in these models. Additionally, we investigated the kinetics of the vascularization process in a colon tumor and a mesothelioma xenograft. In mice bearing a head and neck xenograft, a perfusion study was performed to compare the functionality of the human and mouse tumor vessels.
In patient tumors which successfully engrafted, the human stroma and vessels which were engrafted as part of the original tumor did not survive and were no longer detectable at the time of first passage (15-25 weeks). Uniformly, the stroma and vessels supporting the growth of these tumors were of murine origin. The results of the kinetic studies showed that the loss of the human vessels and vascularization by host vessels occurred more rapidly in a colon tumor (by 3 weeks) than in a mesothelioma (by 9 weeks). Finally, the perfusion studies revealed that while mouse vessels in the periphery of the tumor were perfused, those in the central regions were rarely perfused. No vessels of human origin were detected in this model.
In the tumors we investigated, we found no evidence that the human stromal cells and vessels contained in the original implant either survived or contributed in any substantive way to the growth of these xenografts.
在免疫缺陷小鼠中生长的原发性患者肿瘤异种移植物的研究表明,这些肿瘤在组织学和遗传学上与原始肿瘤非常相似。这些患者异种移植模型正被广泛用于治疗效果研究。由于许多治疗方法针对肿瘤基质成分,并且肿瘤微环境也已知会影响肿瘤对治疗的反应,因此了解基质的性质,特别是异种移植物的血管供应非常重要。
通过将患者肿瘤的未破坏块植入 SCID 小鼠中来建立患者肿瘤异种移植物。在这项研究中,选择了几种类型的实体瘤的福尔马林固定、石蜡包埋标本,并使用与福尔马林固定抗原反应的种特异性抗体,我们分析了支持这些模型中肿瘤生长的基质和血管的种属来源。此外,我们研究了结肠肿瘤和间皮瘤异种移植物中血管生成过程的动力学。在患有头颈部异种移植物的小鼠中,进行了灌注研究以比较人类和小鼠肿瘤血管的功能。
在成功植入的患者肿瘤中,作为原始肿瘤一部分植入的人基质和血管在首次传代(15-25 周)时不再存活且无法检测到。一致地,支持这些肿瘤生长的基质和血管均来自鼠类。动力学研究的结果表明,人血管的丢失和宿主血管的血管生成发生得更快,在结肠肿瘤中(3 周)比间皮瘤中(9 周)更快。最后,灌注研究表明,虽然肿瘤周边的鼠类血管被灌注,但肿瘤中心区域的血管很少被灌注。在该模型中未检测到人类来源的血管。
在我们研究的肿瘤中,我们没有发现证据表明原始植入物中包含的人基质细胞和血管要么存活,要么以任何实质性方式促进这些异种移植物的生长。